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Abstract
Objective 
Status epilepticus (SE) is the most common pediatric neurologic emergency 
with high mortality and morbidity. There is no consensus on the drug of choice 
in the treatment of children. The purpose of this study was to evaluate the 
clinical efficacy and safety of intravenous sodium valproate as a third-line drug 
in the treatment of generalized convulsive SE of children.
Materials & Methods
In a retrospective study, medical records of those children who were admitted 
to Shahid Sadoughi Hospital of Yazd due to refractory generalized convulsive 
SE and were treated by intravenous sodium valproate as a third-line drug from 
2009 to 2011 were evaluated.
Results
Six girls and five boys with a mean age of 5.12 ± 1.2 years (range: 3 - 9.6 years) 
were evaluated. 
Intravenous valproate was effective for cessation of seizures in seven patients 
(63.6%). The mean dose of valproate for stopping seizures was 27.1 ± 1.4 mg/
kg/day.
Children whose seizures were controlled by sodium valproate were older 
than non - responsive children (mean ± SD: 4.8 ± 1.2 years vs. 3.1 ± 0.43 years, 
p = 0.03) and they also had shorter ICU stay days (mean ± SD: 2.6 ± 1.4 days 
vs. 5.6 ± 2.8 days, p= 0.01).
Two children had mild and transient nausea and vomiting. None of them had 
cardiopulmonary or severe paraclinical side effects. 
Conclusion
Intravenous sodium valproate may be used as an effective and safe third-line 
antiepileptic drug in the treatment of pediatric generalized convulsive status 
epilepticus.
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Introduction
Status epilepticus (SE), which is defined as a seizure that persists more than 30 
min or two or more sequential seizures without recovery of consciousness between 
them, is the most common pediatric neurology emergency (1).
Generalized convulsive SE is the most common type that has a significant morbidity 
and mortality (2) which is directly dependent on immediate and appropriate medical 
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therapy. The correct management strategy involves 
initial stabilization of airways, breathing and circulation, 
prompt control of seizures, evaluation and treatment of 
the underlying etiology (1, 3,4).
Refractory status epilepticus (RSE) is defined as ongoing 
seizures despite the use of two first-line drugs, usually a 
benzodiazepine plus either phenytoin or phenobarbital, 
or which continues for more than 60 minutes in spite 
of adequate treatment (3,5). All these patients must 
be managed in a pediatric intensive care unit (ICU) 
with aggressive monitoring of their hemodynamic and 
respiratory status. There is no consensus on the choice 
among available options for treatment of RSE in children 
and the drug of choice in its treatment often depends on 
the experience of a specific center (3).
If cessation of the seizures cannot be achieved, other 
therapeutic strategies such as thiopental, pentobarbital, 
propofol, midazolam drip, intravenous valproate, 
ketogenic diet, lacosamide and intravenous levetiracetam 
may have to be used (1-3, 6-9). 
Valproate is a simple branched-chain carboxylic acid 
with a chemical structure very similar to that of short-
chain fatty acids. Its mechanism of action is not fully 
determined, but it is thought to increase both synthesis 
and release of the inhibitory neurotransmitter of gamma 
amino butyric acid. Usage of valproate in the treatment 
of status epilepticus was approved by the Food and Drug 
Administration in 1997. If seizures do not respond to 
two conventional first-line drugs, intravenous valproate 
may be useful and efficient, especially when the setting 
of intubation and artificial ventilation are not available 
(1, 10 -12).
Although intravenous valproate may be used as a 
second-line antiepileptic drugs in treatment of pediatric 
status epilepticus  (2, 13-15). 
Less than three-year-old children are at a considerably 
increased risk of developing lethal hepatotoxicity, 
especially in those who have a history of hepatic disease, 
taken polytherapy of antiepileptic drugs, or with severe 
seizure disorders accompanied by mental retardation 
(16). 
The purpose of this study was to investigate the clinical 
efficacy and safety of intravenous sodium valproate as a 
third-line drug in the treatment of children’s refractory 
generalized convulsive status epilepticus in Shahid 
Sadoughi Hospital,Yazd, Iran. 
Materials & Methods
In a retrospective study with a non-random census 
sampling method, medical records of all children with 
generalized convulsive status epilepticus who were 
admitted to ICU of Shahid Sadoughi Hospital, Yazd, Iran 
from 2009 to 2011 and were treated with intravenous 
sodium valproate, were evaluated. 
Care was taken to select patients with the below 
mentioned criteria:
1. No history of urea cycle disorder, hepatic diseases 
or kidney dysfunction (either past or present) based 
on history and physical exam, hypotension and 
electrolyte abnormality
2. First time occurrence of status epilepticus
3. BUN, Cr, sodium, potassium, total calcium, and 
glucose in normal limits to exclude electrolyte 
abnormalities and hypoglycemia as the cause of 
seizure
4. Admission to the ICU for aggressive cardiac 
monitoring
5. Seizures not responding to benzodiazepines plus 
either phenytoin and phenobarbital and therefore, 
sodium valproate used as a third-line drug
The risk of developing lethal hepatotoxicity is high in 
less than three-year-old children (16); therefore, in our 
department, sodium valproate treatment is used in older 
than three-year-old children and its protocol in SE was 
as follows:
An initial dose of 15 mg/kg was given intravenously 
at the rate of 3 mg/kg/min and followed by continuous 
infusion of 20 mg/kg/day. If no response was seen or 
seizures recurred, the dose of the drug was increased up 
to 30/mg/kg/day. If the drug was effective in the control 
of seizures, it would be infused with the same dose for 
12 hours and then tapered and ceased during the next 12 
hours. 
Treatment was considered to be effective when 
intravenous sodium valproate stopped clinical seizures.
Blood pressure, electrocardiography, respiratory rate and 
oxygen saturation were continuously monitored to detect 
cardiopulmonary complications. Liver function tests, 
complete blood count and ammonia level were measured 
daily. Measurement of serum sodium valproate level 
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as hepatotoxicity, thrombocytopenia with abnormal 
bleeding and severe hyperammonemia. 
Discussion
Intravenous valproate can be used as an alternative to 
phenobarbital and phenytoin in the treatment of seizures 
and epileptic syndromes, especially in allergic patients 
and in progressive myoclonus epilepsy. Lack of life 
threatening cardiovascular, neurological, or local adverse 
effects supported its use in emergency conditions as well 
(9).
A few researches have been carried out regarding the use 
of intravenous valproate in pediatric SE.
In the present study, intravenous valproate as a third-line 
drug was effective in controlling generalized seizures 
that were refractory to benzodiazepine and phenytoin or 
phenobarbital in 63.6% of children and this efficacy rate 
is similar to 63.3% in another study (17,18).
Other studies of valproate effectiveness for seizure 
control in pediatric SE showed a response rate ranging 
from 58 to 100% (9, 12, 17-24). Possible explanations 
for these discrepancies are differences in race, sample 
size, patient age and drug dosage.
In a systematic review, Sofou et al. concluded that 
intravenous valproate as a third-line drug was effective 
and safe in children’s convulsive status epilepticus 
which was refractory to diazepam and phenytoin (11).
On the other hand, in a study in Taiwan, Chang et al. 
concluded that intravenous valproate can be used as the 
first choice in the treatment of SE and acute repetitive 
seizures in children (9).
In a randomized unblinded study, Misra et al.’s study 
found that in the treatment of SE, valproate was superior 
both as a first-line (66% vs. 42%) and second-line (79% 
vs. 25%) drug (15). 
In the present study, the mean dose of valproate for 
stopping seizures was 27.1 ± 1.4 mg/kg/day which is 
lower than the study in Taiwan (31.2 ± 26.45 mg/kg/day) 
(9). Sodium valproate is often used in a dosage of 20-30 
mg/kg at a rate of about 3 mg/kg/min and it may also be 
administered as a rapid intravenous infusion for up to 6 
mg/kg/min to a maximum dose of 45 mg/kg (16). 
The results of this study also indicate that undesirable 
side effects were not seen in valproate use. Safety results 
of this study support other ones (9, 19-24). None of 
and video electroencephalography monitoring were not 
available in our hospital.
If seizures were not stopped with the maximum dose 
of sodium valproate infusion drip, it was regarded to 
be unsuccessful, so the drug use was discontinued and 
benzodiazepines or pentobarbital drip was introduced.
The data were gathered from the patient’s medical 
records in pediatric ICU. Variables such as age, sex, 
neuroimaging and EEG findings, neurodevelopmental 
delay, seizure control, adverse effects (hypotension, 
respiratory depression needing intubation and 
mechanical ventilation, gastrointestinal upset, dizziness, 
headache, hepatotoxicity, hyperammonemia and 
thrombocytopenia) and days of stay in the ICU were 
carefully recorded. Informed consent was obtained from 
the subjects’ parents. 
Results
Eleven children including six girls (54.5 %) and five 
boys (45.5%) with the mean age of 5.12 ± 1.2 years 
(range: 3 - 9.6 years), were evaluated.
From the viewpoint of etiologic classification of status 
epilepticus, eight (72.7%) were symptomatic, two 
(18.2%) idiopathic and one (9.1%) was febrile status 
epilepticus. Symptomatic etiologies included inborn 
error of metabolism in four (50%), encephalitis in 
two (25%), each of poisoning and hypoxic ischemic 
encephalopathy in one child (12.5%).
The seizure type was generalized tonic- clonic in 
seven (63.6%), generalized clonic in three (27.3%) and 
generalized tonic in one (9.1%) patient.
Intravenous valproate was effective for cessation of 
seizures in seven patients (63.6 %) and the mean dose 
of valproate for stopping of seizures was 27.1 ± 1.4 mg/
kg/day.
Comparison of some clinical and paraclinical 
characteristics of patients based on seizure control are 
presented in Table I which indicates that the mean age 
of patients whose seizures were controlled by sodium 
valproate was more than non- responsive children and 
the patients whose seizures did not stop by sodium 
valproate had a prolonger ICU stay.
Two children had mild and transient nausea and vomiting. 
None of them had cardiopulmonary complications 
or severe clinical and paraclinical side effects such 
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valproate use is cost-effective considering no respiratory 
depression and also no need for ventilator support 
coincided with short stay days in the ICU.
The limitations of this study were lack of video-EEG 
monitoring and its inability to recognize electrographic 
seizure cessation and the small number of our patients. 
Therefore, it is necessary to conduct randomized clinical 
trials to evaluate and compare the efficacy of intravenous 
valproate and other antiepileptic drugs in the treatment 
of pediatric refractory status epilepticus. 
We conclude that intravenous valproate can be used 
as a safe and effective third-line, antiepileptic drug in 
children’s status epilepticus.
If patients have chronic respiratory disease or severe 
disability and respiratory impairment or wherever 
management of respiratory depression (intubation 
and artificial ventilation) is not available, intravenous 
valproate might be used as the first choice in the treatment 
of convulsive status epilepticus. 
the patients in the present study required ventilation or 
developed hypotension. Cardiovascular side effects such 
as hypotension or arrhythmia and respiratory depression 
are rare in administration of intravenous valproate even 
in high doses and rapid infusions (25) and since the 
drug showed no hemodynamic adverse effects, it can 
be useful in SE of children and elderly patients with 
cardiovascular instability who may be at increased risk 
for adverse reactions due to phenytoin/fosphenytoin 
(21,26,27).
The incidence of side effects in patients taking intravenous 
valproate is low (less than 10%). These side effects are 
mainly hypotension, dizziness and thrombocytopenia 
(17) and the drug seems to be well tolerated in patients 
with SE (27). Valproate hepatotoxicity which has been 
explained as four distinct subtypes; namely, a transient 
elevation of liver enzymes, hyperammonemia, toxic 
hepatitis and a Reye-like syndrome (26) are rare above 
the age of three and in monotherapy (16).
Based on results of the present study, intravenous 
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Table 1. Comparison of Children’s Characteristics Based on Seizure Control 





Age in year (Mean ± SD) 4.8 ± 1.2 3.1 ± 0.43 0.03









Type of Seizure 
Generalized tonic-clonic 4 3
0.7Generalized clonic 2 1
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